These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 20463796)

  • 21. Incidence of and risk factors for visual acuity loss among patients with AIDS and cytomegalovirus retinitis in the era of highly active antiretroviral therapy.
    Thorne JE; Jabs DA; Kempen JH; Holbrook JT; Nichols C; Meinert CL;
    Ophthalmology; 2006 Aug; 113(8):1432-40. PubMed ID: 16766032
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long term visual outcome of patients with cytomegalovirus retinitis treated with highly active antiretroviral therapy.
    Goldberg DE; Wang H; Azen SP; Freeman WR
    Br J Ophthalmol; 2003 Jul; 87(7):853-5. PubMed ID: 12812884
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ocular manifestations of AIDS: new considerations for patients using highly active anti-retroviral therapy (HAART).
    Roels P
    Optometry; 2004 Oct; 75(10):624-8. PubMed ID: 15508863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advances in the management of AIDS-related cytomegalovirus retinitis.
    Masur H; Whitcup SM; Cartwright C; Polis M; Nussenblatt R
    Ann Intern Med; 1996 Jul; 125(2):126-36. PubMed ID: 8678367
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Visual loss in patients with cytomegalovirus retinitis and acquired immunodeficiency syndrome before widespread availability of highly active antiretroviral therapy.
    Holbrook JT; Jabs DA; Weinberg DV; Lewis RA; Davis MD; Friedberg D;
    Arch Ophthalmol; 2003 Jan; 121(1):99-107. PubMed ID: 12523893
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 5. Clinical features of cytomegalovirus retinitis at diagnosis. Studies of ocular complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group.
    Am J Ophthalmol; 1997 Aug; 124(2):141-57. PubMed ID: 9262538
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New strategies for the management of AIDS-related CMV retinitis in the era of potent antiretroviral therapy.
    Holland GN
    Ocul Immunol Inflamm; 1999 Dec; 7(3-4):179-88. PubMed ID: 10611726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy.
    Kedhar SR; Jabs DA
    Herpes; 2007 Dec; 14(3):66-71. PubMed ID: 18371289
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intraocular therapy for cytomegalovirus retinitis.
    Palestine AG
    J Int Assoc Physicians AIDS Care; 1996 May; 2(5):25-8. PubMed ID: 11363527
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy.
    Whitcup SM
    JAMA; 2000 Feb; 283(5):653-7. PubMed ID: 10665706
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial. The Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group.
    Arch Ophthalmol; 1996 Jan; 114(1):23-33. PubMed ID: 8540847
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Stopping secondary prevention in AIDS patients with inactive CMV retinitis treated with HAART (highly active antiretroviral therapy)].
    Best J; Althaus C; Kersten A; Theisen A; Gantke B
    Ophthalmologe; 2000 Aug; 97(8):574-6. PubMed ID: 10994337
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Intravitreal injection of ganciclovir in AIDS patients with cytomegalovirus retinitis].
    Fujino Y; Nagata Y; Miyoshi M; Ono A; Oka S; Iwamoto A; Kimura S; Mochizuki M
    Nippon Ganka Gakkai Zasshi; 1996 Aug; 100(8):634-40. PubMed ID: 8810241
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: five-year outcomes.
    Jabs DA; Ahuja A; Van Natta M; Lyon A; Srivastava S; Gangaputra S;
    Ophthalmology; 2010 Nov; 117(11):2152-61.e1-2. PubMed ID: 20673591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of CMV retinopathy in patients with AIDS.
    Tay-Kearney ML; Jabs DA
    Ocul Immunol Inflamm; 1996; 4(2):113-8. PubMed ID: 22827416
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytomegalovirus retinitis: diagnosis and status of systemic therapy.
    Friedberg DN
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997; 14 Suppl 1():S1-6. PubMed ID: 9058611
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ganciclovir implants: one year later.
    Cadman J
    GMHC Treat Issues; 1997; 11(4/5):3-6. PubMed ID: 11364375
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy in HIV infected patients: natural history and clinical predictors.
    Lin DY; Warren JF; Lazzeroni LC; Wolitz RA; Mansour SE
    Retina; 2002 Jun; 22(3):268-77. PubMed ID: 12055458
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes associated with ganciclovir implants in patients with AIDS-related cytomegalovirus retinitis.
    Kappel PJ; Charonis AC; Holland GN; Narayanan R; Kulkarni AD; Yu F; Boyer DS; Engstrom RE; Kuppermann BD;
    Ophthalmology; 2006 Apr; 113(4):683.e1-8. PubMed ID: 16581428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of cytomegalovirus retinitis on the quality of life of patients with AIDS in the era of highly active antiretroviral therapy.
    Kempen JH; Martin BK; Wu AW; Barron B; Thorne JE; Jabs DA;
    Ophthalmology; 2003 May; 110(5):987-95. PubMed ID: 12750102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.